To increase value through global activities ensuring the delivery of highly sensitive, novel and robust test(s) for early detection of cancer, assessment of cancer treatments and assistance in drug development.
Sienna is a biotechnology company based in Melbourne Australia. With the help of their large global clinical networks, Sienna is able to drive the discovery and development of novel IVD (in vitro diagnostic) tests for cancer. Sienna manufactures individual component products for research institutions and pathology laboratories to use in research or in their own laboratory developed tests. Sienna’s experienced and diverse team is responsible for the launch of their first product in 2014 in the USA, the anti-hTERT antibody (SCD-A7).
The standard techniques used in the monitoring and diagnosis of bladder cancer are urine cytology and cystoscopy, the latter being visual inspection and possible resection of cancerous lesions identified on the bladder wall using an endoscope. Existing tests have limited sensitivity and specificity in the detection of cancer, and cystoscopy is an invasive procedure for the patient, and a costly one for the healthcare system. Sienna expects to develop IVD tests to be used in new, simple non-invasive tests for bladder cancer, and other cancer indications.
The human telomerase reverse transcriptase (hTERT) protein is an 1132-amino acid protein that forms part of the protein complex of human telomerase. Telomerase is in part responsible for telomere maintenance, which is regarded as an important mechanism by which tumour cells evade senescence, which in most cases is achieved by reactivating or up-regulating telomerase activity. Telomerase is reported as activated in 80–90% of human carcinomas and present in circulating cancer cells.
In May 2014 Sienna Cancer Diagnostics announced the successful registration of its lead product, Anti-hTERT antibody (SCD-A7), with the US Food and Drug Administration (FDA).
Given the established power of the telomerase biomarker in correlating with malignancy, global pathology labs …
The Commercialisation grant will enable Sienna to advance its clinical evaluation programmes, progress its initial licencing agreements in the USA (the world’s largest market) and recruit new senior staff to drive its global product launch.
Sienna’s Managing Director and CEO …